Parameters | Controls (n=30) | Patients without MHE (n=30) | Patients with MHE (n=22) | Patients with MHE (n=22) | |||
---|---|---|---|---|---|---|---|
“Responder” patients (n=13) | “Non-responder” patients (n=9) | ||||||
Before rifaximin | After rifaximin treatment | Before rifaximin | After rifaximin treatment | ||||
Gender (M/F) | 19/11 | 24/6 | 19/3 | 11/2 | 8/1 | ||
Age | 59 ± 1 | 61 ± 1 | 63 ± 2 | 60 ± 2 | 63 ± 2 | ||
Alcohol | 19 | 12 | 7 | 5 | |||
HBV/HCV | 9 | 5 | 4 | 1 | |||
Others | 2 | 5 | 2 | 3 | |||
Ascites | 2 | 6 | 2 | 2 | 1 | 1 | |
Child Pugh A/B/C | 26A/4B | 13A/6B/3C | 9A/4B | 8A/5B | 6A/2B/1C | 5A/3B/1C | |
MELD | 10 ± 1 | 11 ± 1 | 10 ± 1 | 10 ± 1 | 11 ± 2 | 12 ± 2 | |
Haemoglobin (g/dL) | 14.6 ± 0.2 | 13.7 ± 0.5 | 13.1 ± 0.4 | 13 ± 0.6* | 13 ± 0.7* | 13.7 ± 0.4 | 13.4 ± 0.7 |
Total bilirubin (mg/dL) | 0.5 ± 0.03 | 1.3 ± 0.2** | 1.2 ± 0.2* | 1.1 ± 0.2* | 1.2 ± 0.1* | 1.3 ± 0.4* | 1.5 ± 0.5* |
Albumin (g/dL) | 4.5 ± 0.1 | 3.8 ± 0.2** | 3.7 ± 0.1*** | 3.7 ± 0.2** | 3.8 ± 0.2** | 3.7 ± 0.2** | 3.6 ± 0.4** |
ALT (U/L) | 23 ± 2 | 36 ± 3* | 33 ± 3 | 32 ± 4 | 27 ± 4 | 29 ± 3 | 34 ± 3 |
Sodium (mM) | 138 ± 0.3 | 139 ± 0.7 | 137 ± 2 | 136 ± 1 | 139 ± 1aa | 138 ± 3 | 136 ± 3a |
Creatinin (mg/dL) | 0.77 ± 0.02 | 0.78 ± 0.03 | 0.88 ± 0.05 | 0.84 ± 0.06 | 0.81 ± 0.07 | 0.95 ± 0.11* | 0.89 ± 0.15 |
INR | 1.05 ± 0.01 | 1.34 ± 0.05*** | 1.22 ± 0.05* | 1.19 ± 0.04*** | 1.28 ± 0.08*** | 1.24 ± 0.1** | 1.21 ± 0.07*** |
Ammonia (μM) | 9 ± 1 | 27 ± 4* | 41 ± 8*** | 38 ± 11** | 34 ± 7* | 46 ± 12*** | 48 ± 13*** |